Aisling Capital believes the next decade will be marked by a revolution in healthcare driven by new therapeutics generated by
Aisling Capital believes the next decade will be marked by a revolution in healthcare driven by new therapeutics generated by biotechnology. The completion of the human genome has given scientists new insights into the causes of human disease. These insights, combined with the past 20 years of developments in the biotechnology industry, are leading to rapid expansion of novel approaches toward the diagnosis, prevention, and treatment of life-threatening illnesses. These advances have led to an ever-increasing demand for capital to complete the development and commercialization of new therapeutics. Our goal is to support the leading global healthcare companies that are building on these technical and medical breakthroughs to commercialize new healthcare products.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Sep 12, 2022
Forge Biologics
|
Series C | $90M | Biotechnology | Yes |
Nov 13, 2017
Arcus Biosciences
|
Series C | $107M | Biotechnology | — |
Jun 8, 2016
Miramar Labs
|
Series Unknown | — | Health Care | — |
Jul 24, 2015
ViewRay
|
Post-IPO Equity | $26.70M | Biotechnology | — |
Oct 6, 2014
Miramar Labs
|
Series D | $26M | Health Care | — |